Pipeline
ABL103
HomePipelineABL103
-
- Pipeline
- ABL103
-
- Program Target
- B7-H4x4-1BB
-
- Disease Indication
- Solid Cancer
-
- Development Stage
- IND enabling study
- Summary
- A novel T-cell engaging bispecific antibody, ABL103 demonstrates efficacious anti-tumor activity via B7-H4 mediated 4-1BB activation in tumor microenvironments (TME), only activating 4-1BB signaling pathways when in the presence of B7-H4 expressing cells. ABL103 strongly inhibits tumor growth and induces immunological memory to create prolonged anti-tumor protection.
Structure and Mechanism of Action
B7-H4 Dependent 4-1BB Activation
ABL103 induces more significant cell lysis than Urelumab with B7-H4 dependent 4-1BB activation
Superior Anti-Tumor Effect with Immunological Memory
ABL103 Completely eliminates tumors in advanced tumor model and protects mice from re-challenge with MC38-B7-H4 tumor
